长风药业（02652）今日盘中大涨5.04%，延续上市首日的强劲势头。该公司于10月8日在港交所主板挂牌上市，首日股价就大幅上涨161.02%，显示出市场对这家专注于呼吸系统吸入制剂研发的企业的高度认可。
长风药业此次全球发售4119.8万股H股，发行价为每股14.75港元，共募集资金净额约5.25亿港元。公司计划将募集资金用于推进国内外在研产品的临床开发、新管线的临床前研究，以及生产设施与管理系统的升级扩建，进一步推动其国际化布局。
分析人士认为，长风药业的产品线覆盖哮喘、慢性阻塞性肺病及过敏性鼻炎等高需求领域，且具备四大技术平台，在吸入制剂领域具有较强竞争力。此次上市不仅为公司提供了充足的资金支持，也有望帮助其加快产品研发进程，扩大市场份额，这些因素都是推动股价上涨的重要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.